ATE272719T1 - Der entwurf von medikamenten, die in die rezeptor-ligand-dna wechselwirkungen eingreifen - Google Patents

Der entwurf von medikamenten, die in die rezeptor-ligand-dna wechselwirkungen eingreifen

Info

Publication number
ATE272719T1
ATE272719T1 AT95904188T AT95904188T ATE272719T1 AT E272719 T1 ATE272719 T1 AT E272719T1 AT 95904188 T AT95904188 T AT 95904188T AT 95904188 T AT95904188 T AT 95904188T AT E272719 T1 ATE272719 T1 AT E272719T1
Authority
AT
Austria
Prior art keywords
ligand
dna
receptor
receptors
drugs
Prior art date
Application number
AT95904188T
Other languages
English (en)
Inventor
Lawrence B Hendry
Original Assignee
Lawrence B Hendry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lawrence B Hendry filed Critical Lawrence B Hendry
Application granted granted Critical
Publication of ATE272719T1 publication Critical patent/ATE272719T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/50—Molecular design, e.g. of drugs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • G16C20/64—Screening of libraries

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Evolutionary Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medical Informatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Computing Systems (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Library & Information Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT95904188T 1993-11-26 1994-11-28 Der entwurf von medikamenten, die in die rezeptor-ligand-dna wechselwirkungen eingreifen ATE272719T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15868993A 1993-11-26 1993-11-26
PCT/US1994/013765 WO1995014791A1 (en) 1993-11-26 1994-11-28 Design of drugs involving receptor-ligand-dna interactions

Publications (1)

Publication Number Publication Date
ATE272719T1 true ATE272719T1 (de) 2004-08-15

Family

ID=22569263

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95904188T ATE272719T1 (de) 1993-11-26 1994-11-28 Der entwurf von medikamenten, die in die rezeptor-ligand-dna wechselwirkungen eingreifen

Country Status (8)

Country Link
US (5) US5705335A (de)
EP (1) EP0740708B1 (de)
JP (1) JPH09505603A (de)
AT (1) ATE272719T1 (de)
AU (1) AU1297995A (de)
CA (1) CA2177388A1 (de)
DE (1) DE69433935D1 (de)
WO (1) WO1995014791A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660842B1 (en) * 1994-04-28 2003-12-09 Tripep Ab Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
US6040137A (en) * 1995-04-27 2000-03-21 Tripep Ab Antigen/antibody specification exchanger
US6933366B2 (en) * 1996-12-27 2005-08-23 Tripep Ab Specificity exchangers that redirect antibodies to bacterial adhesion receptors
US5978740A (en) * 1995-08-09 1999-11-02 Vertex Pharmaceuticals Incorporated Molecules comprising a calcineurin-like binding pocket and encoded data storage medium capable of graphically displaying them
WO1997026277A2 (en) 1996-01-22 1997-07-24 Creative Biomolecules, Inc. Morphogen analogs and methods for producing them
US5891646A (en) * 1997-06-05 1999-04-06 Duke University Methods of assaying receptor activity and constructs useful in such methods
US6528271B1 (en) * 1997-06-05 2003-03-04 Duke University Inhibition of βarrestin mediated effects prolongs and potentiates opioid receptor-mediated analgesia
US7541151B2 (en) 1997-06-05 2009-06-02 Duke University Single-cell biosensor for the measurement of GPCR ligands in a test sample
ATE219847T1 (de) 1997-09-05 2002-07-15 Accelrys Inc Interaktionsmodellierung mit atomaren parametern und anisotropischer dipol-polarisierbarkeit
US7020563B1 (en) * 1997-11-27 2006-03-28 Commonwealth Scientific And Industrial Research Organisation Method of designing agonists and antagonists to IGF receptor
AU3901099A (en) * 1998-05-12 1999-11-29 Isis Pharmaceuticals, Inc. Characterization of interactions between molecular interaction sites of rna and ligands therefor
AUPP380498A0 (en) * 1998-05-29 1998-06-25 Biomolecular Research Institute Limited Egf receptor agonists and antagonists
US20010041964A1 (en) * 1998-09-14 2001-11-15 George M. Grass Pharmacokinetic-based drug design tool and method
KR100303263B1 (ko) * 1998-10-13 2001-12-01 조양호 벡터를이용한rna분자이차구조의시각화방법
US6298259B1 (en) 1998-10-16 2001-10-02 Univ Minnesota Combined magnetic resonance imaging and magnetic stereotaxis surgical apparatus and processes
US7083777B1 (en) * 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
US6343257B1 (en) * 1999-04-23 2002-01-29 Peptor Ltd. Identifying pharmacophore containing combinations of scaffold molecules and substituents from a virtual library
US6969763B1 (en) 1999-05-12 2005-11-29 Isis Pharmaceuticals, Inc. Molecular interaction sites of interleukin-2 RNA and methods of modulating the same
US20030083483A1 (en) * 1999-05-12 2003-05-01 Ecker David J. Molecular interaction sites of vimentin RNA and methods of modulating the same
WO2001071347A1 (en) * 2000-03-23 2001-09-27 California Institute Of Technology Method and apparatus for predicting ligand binding interactions
WO2002041184A1 (en) * 2000-11-14 2002-05-23 Kyorin Pharmaceutical Co., Ltd. Method of searching for novel lead compound
SV2003000753A (es) 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
WO2002046392A2 (en) 2000-12-09 2002-06-13 The Regents Of The University Of California X ray crystal structures at 5.5 a resolution of functional complexes of the bacterial ribosome containing transfer rna and model messenger rnas
US20030162219A1 (en) * 2000-12-29 2003-08-28 Sem Daniel S. Methods for predicting functional and structural properties of polypeptides using sequence models
US20030013137A1 (en) * 2001-03-13 2003-01-16 Barak Larry S. Automated methods of detecting receptor activity
AU2002305274A1 (en) * 2001-04-27 2002-11-11 The General Hospital Corporation 3-structure of a whole integrin $g(a)v$g(b)3 extracellular region and uses therefor
EP1520244A4 (de) * 2001-10-23 2006-08-30 Pharmacogenetics Dev Company I Systeme und verfahren zum schnellen bewerten und entwerfen von molekülen für eine vorhergesagte biologische aktivität
US20040067512A1 (en) * 2001-11-09 2004-04-08 Neurogenetics, Inc. Single nucleotide polymorphisms and mutations on Alpha-2-Macroglobulin
AU2002364894A1 (en) * 2001-11-09 2003-06-30 Neurogenetics, Inc. Single nucleotide polymorphisms and mutations on alpha-2-macroglobulin
US20030182669A1 (en) * 2002-03-19 2003-09-25 Rockman Howard A. Phosphoinositide 3-kinase mediated inhibition of GPCRs
EP1535235A1 (de) * 2002-05-28 2005-06-01 The Trustees of The University of Pennsylvania Verfahren, systeme und computerprogrammprodukte zur rechnerischen analyse und den entwurf von amphiphilischen polymeren
US7290215B2 (en) * 2002-06-03 2007-10-30 Microsoft Corporation Dynamic wizard interface system and method
WO2004035789A1 (en) 2002-10-18 2004-04-29 Lg Life Sciences Ltd. Gene families associated with cancers
AU2003287250B9 (en) 2002-10-30 2010-01-28 Ptc Therapeutics, Inc. Identifying therapeutic compounds based on their physical-chemical properties
US7335359B2 (en) 2003-02-06 2008-02-26 Tripep Ab Glycosylated specificity exchangers
EP2230249A3 (de) 2003-02-06 2010-12-22 ChronTech Pharma AB Antigen/Antikörper oder Ligand/Rezeptor glycosylierter Spezifität Austauscher
WO2004089407A2 (en) 2003-03-31 2004-10-21 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
US8345988B2 (en) * 2004-06-22 2013-01-01 Sri International Method and apparatus for recognizing 3-D objects
US20060052943A1 (en) * 2004-07-28 2006-03-09 Karthik Ramani Architectures, queries, data stores, and interfaces for proteins and drug molecules
US8206726B2 (en) 2006-02-06 2012-06-26 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
KR100954322B1 (ko) 2006-06-14 2010-04-21 주식회사 엘지생명과학 췌장암과 관련된 신규한 ｌｂｆｌ313 유전자
US20090092631A1 (en) * 2007-03-26 2009-04-09 Tripep Ab Glycosylated specificity exchangers that induce an antibody dependent cellular cytotoxicity (adcc) response
WO2008154456A2 (en) * 2007-06-06 2008-12-18 Nationwide Children's Hospital, Inc. Methods and compositions relating to viral fusion proteins
WO2009009493A2 (en) 2007-07-09 2009-01-15 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES Aegyptin and uses thereof
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
US9539281B2 (en) 2011-07-12 2017-01-10 The Brigham And Women's Hospital, Inc. Lipid-containing PSA compositions, methods of isolation and methods of use thereof
CN102798708A (zh) * 2012-08-23 2012-11-28 中国科学院长春应用化学研究所 一种检测配体与靶标结合特异性的方法及药物筛选方法
JP6918365B2 (ja) 2015-08-19 2021-08-11 プレジデント アンド フェローズ オブ ハーバード カレッジ 脂質化ｐｓａ組成物および方法
US11491181B2 (en) 2016-07-15 2022-11-08 President And Fellows Of Harvard College Glycolipid compositions and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4461619A (en) * 1981-12-29 1984-07-24 Medical College Of Georgia Research Inst. Method of predicting biological activity of compounds by nucleic acid models
US4705796A (en) * 1986-08-25 1987-11-10 Stereochemical Genetics, Inc. Use of 3-N-phenylacetylamino-2,6-piperidinedione for treatment of neuropsychiatric disorders
US5025388A (en) * 1988-08-26 1991-06-18 Cramer Richard D Iii Comparative molecular field analysis (CoMFA)
US5238947A (en) * 1990-04-12 1993-08-24 University Of Georgia Research Foundation, Inc. Synthetic piperidinediones with cytostatic activity
WO1991016309A1 (en) * 1990-04-12 1991-10-31 University Of Georgia Research Foundation, Inc. Synthetic piperidinediones with cytostatic activity

Also Published As

Publication number Publication date
EP0740708A4 (de) 1999-12-01
WO1995014791A1 (en) 1995-06-01
US5888741A (en) 1999-03-30
AU1297995A (en) 1995-06-13
CA2177388A1 (en) 1995-06-01
EP0740708A1 (de) 1996-11-06
US6306595B1 (en) 2001-10-23
JPH09505603A (ja) 1997-06-03
US20020064790A1 (en) 2002-05-30
US5705335A (en) 1998-01-06
EP0740708B1 (de) 2004-08-04
DE69433935D1 (de) 2004-09-09
US5888738A (en) 1999-03-30

Similar Documents

Publication Publication Date Title
ATE272719T1 (de) Der entwurf von medikamenten, die in die rezeptor-ligand-dna wechselwirkungen eingreifen
DE69627031D1 (de) Dateiprozessor für die verteilung von multimedia-dateien
JP2012001548A (ja) 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法
DE60041589D1 (de) Reparieren von anwendungen, die inkompatibel zum betriebssystem sind durch bereitstellung von stubs für api's
WO2002054194A3 (en) Adaptive software installation process supporting multiple layers of security-related attributes
AP9901654A0 (en) Gene sequencer and methods.
NZ507887A (en) Soluble T cell receptor
EP1517235A3 (de) Rahmenwerk zur Markenbildung
TW347518B (en) Display screen split method of a computer system
Nakajima et al. Effect of pancreatic type phospholipase A2 on isolated porcine cerebral arteries via its specific binding sites
MY118655A (en) Method and apparatus for determining the drive letter assignment of a cd-rom drive during initial system setup of a computer system
WO2004088509A3 (en) Apparatus, system and method of appending a group of files to files on a clipboard of a desktop
ATE214554T1 (de) Gekochte wurst und verfahren zu ihrer herstellung
EP1069050A3 (de) Klammer
Kuiper et al. Androgen receptor heterogeneity in LNCaP cells is caused by a hormone independent phosphorylation step
Brosnihan et al. Estrogen, nitric oxide, and hypertension differentially modulate agonist-induced contractile responses in female transgenic (mRen2) 27 hypertensive rats
Suarez et al. Upregulation of angiotensin II type 2 receptor expression in estrogen-induced pituitary hyperplasia
EP1319089A4 (de) In vitro testverfahren zur bestimmung der immunogenizität eines impfstoffes
Gyug AN EDITION OF LENINGRAD, BAN, F. NO. 200: THE LECTIONARY AND PONTIFICAL OF KOTOR.
Meli et al. Eicosanoids in human breast cancer. Relationship to estrogen, progesterone and prolactin receptor status
Palmiter et al. Kinetics of ovalbumin and conalbumin mRNA induction by estrogen and progesterone
AU7269100A (en) Method for indirectly determining the blood-clotting status
Carnathan Progesterone withdrawal during midpregnancy in rats: the effect of treatment and duration of withdrawal.
Ferrini et al. Estradiol increases glucocorticoid binding and glucocorticoid induction of ornithine decarboxylase in the rat spinal cord
Song Mixing visual and textual programming in a functional language.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties